Theriva Biologics, Inc. (TOVX) Dividend History

Company News

• US Stocks To Open Higher On Shortened Trading Day: Santa Claus Rally Period Officially Begins, Says Analyst

  US stock futures are trading higher ahead of a shortened trading session on Christmas Eve. Analysts expect a 'Santa Rally' during this period, which has historically seen positive returns. However, they also caution about potential market corrections in 2025 due to stretched valuations.

  Benzinga

  Featured Companies: CREV NEUE QQQ SPY TIVC
• Theriva™ Biologics anuncia la orientación de la FDA estadounidense con respecto al diseño del estudio de Fase 3 del VCN-01 para el tratamiento del cáncer de páncreas metastásico

  Theriva Biologics announced that the FDA provided guidance on the design of a Phase 3 study for their lead candidate VCN-01 in combination with standard chemotherapy for the treatment of metastatic pancreatic cancer. The FDA recommended conducting an independent Phase 3 study of VCN-01 with gemcitabine/nab-paclitaxel, rather than expanding the ongoing Phase 2b VIRAGE study.

  GlobeNewswire Inc.
• Theriva™ Biologics Announces U.S. FDA Guidance on Design of Phase 3 Study of VCN-01 for the Treatment of Metastatic Pancreatic Cancer

  Theriva Biologics announced that the FDA provided guidance on the design of a Phase 3 clinical study of VCN-01 in combination with standard-of-care chemotherapy for the treatment of metastatic pancreatic adenocarcinoma (PDAC). The FDA advised that the ongoing VIRAGE Phase 2b study should not be expanded into a Phase 3 study, and instead, a stand-alone Phase 3 study of VCN-01 with gemcitabine/nab-paclitaxel should be conducted.

  GlobeNewswire Inc.
• Theriva Biologics seleccionada como finalista en el concurso internacional para las becas del programa Advance Biotech Grant en la región EMEA de Merck KGaA

  Theriva Biologics, a clinical-stage biopharmaceutical company, has been selected as one of the five finalists for the Advance Biotech Grant in the EMEA region of Merck KGaA. The company will present its lead candidate VCN-01, an oncolytic adenovirus, at the BIO-Europe 2024 conference in Stockholm.

  GlobeNewswire Inc.
• Theriva™ Biologics anuncia el resultado positivo de la revisión del Comité de vigilancia y seguridad de los datos en el ensayo clínico de Fase 1b/2a de SYN-004 (ribaxamasa) en receptores de trasplantes alogénicos de células hematopoyéticas

  Theriva Biologics announced positive results from the Data Safety Monitoring Committee (DSMC) review of the second cohort of its Phase 1b/2a clinical trial of SYN-004 (ribaxamasa) in allogeneic hematopoietic stem cell transplant recipients. The DSMC recommended proceeding to enroll patients in the third cohort, where the study drug will be administered with the intravenous beta-lactam antibiotic cefepime.

  GlobeNewswire Inc.